New Treatment Option for Patients with HER2+ Gastroesophageal Junction Adenocarcinoma
The U.S. Food & Drug Administration has approved a new therapy for adult patients with locally advanced or metastatic HER2+ [...]
The U.S. Food & Drug Administration has approved a new therapy for adult patients with locally advanced or metastatic HER2+ [...]
The latest statistics released by the American Cancer Society projects that fewer Americans will die of Esophageal Cancer in 2021 [...]
Findings of three studies important to Esophageal Cancer patients were presented at the 2020 ESMO (European Society of Medical Oncology) [...]
Results of a clinical study called PANGEA (Personalized ANtibodies for GastroEsophageal Adenocarcinoma) found survival benefits for patients when compared to [...]
The early results of two large, Phase III clinical trials of the immunotherapy Opdivo (nivolumab) showed significant survival benefits for [...]
The familial connection is one of the Strongest Indicators of Risk according to Experts. ECAN spoke with the Leading Researcher [...]
First Time the FDA has given Breakthrough Designation for a Device Targeting Diseases of the Esophagus. Lucid Diagnostics' EsoGuard™ Esophageal [...]
The U.S. Food and Drug Administration has approved Keytruda (Pembrolizumab) for treatment of advanced Esophageal Squamous Cell Carcinoma (ESCC). It [...]
First Esophageal Cancer patient is dosed in Phase 3 clinical trial using immune checkpoint inhibitor Tyvyt (sintilimab injection), in [...]
Unprecedented International Collaboration will Focus on Esophageal and other Cancers with $26 Million UK Grant. Read more about this [...]